Analyst upgrades typically lead to positive short-term price movements as they reflect a positive change in the analyst's view of the company's future prospects. The upgrade from Neutral to Buy suggests a strong confidence in Mersana Therapeutics' potential for growth, and the $7 price target indicates a significant upside from the current trading price. This is likely to attract investor interest and potentially drive up the stock price in the short term.